The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials.
Adnan Malik, Waseem Amjad, Faisal Inayat, Mahum Nadeem, Simcha Weissman, Muhammad Imran Malik, Ans Ahmad Jajja, Ahmad Khan, James H Tabibian
{"title":"The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials.","authors":"Adnan Malik, Waseem Amjad, Faisal Inayat, Mahum Nadeem, Simcha Weissman, Muhammad Imran Malik, Ans Ahmad Jajja, Ahmad Khan, James H Tabibian","doi":"10.5114/pg.2022.112775","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease, but no drug therapies have been approved to date. While glucagon-like peptide-1 (GLP-1) analogues may help in the management, the existing evidence remains conflicting.</p><p><strong>Aim: </strong>This meta-analysis aims to elucidate the efficacy of liraglutide in patients with NASH.</p><p><strong>Material and methods: </strong>We searched 4 databases for randomized controlled trials assessing the efficacy of liraglutide in patients with NASH. We analysed continuous outcomes using the mean difference (MD) and relative 95% confidence interval (CI), while dichotomous outcomes were analysed using the risk ratio (RR) and relative 95% CI. Primary endpoints included alanine aminotransferase (ALT) (IU/l), aspartate aminotransferase (AST) (IU/l), alkaline phosphatase (ALP) (IU/l), and γ-glutamyl transferase (GGT) (IU/l). Secondary outcomes were body mass index (BMI) (kg/m<sup>2</sup>), waist circumference (cm), total cholesterol (TC) (mmol/l), triglyceride (TG) (mmoll), high-density lipoprotein (HDL) (mmol/l), low-density lipoprotein (LDL) (mmol/l), and glycated hemoglobin (HbA<sub>1c</sub>) (%).</p><p><strong>Results: </strong>A total of 5 clinical trials were included. The analysis showed that liraglutide is effective in increasing HDL (MD = +0.10 (-0.18, -0.02), <i>p</i> = 0.02) and reducing LDL levels in blood (MD = -0.29 (-0.56, -0.02), <i>p</i> = 0.04). No significant difference was noted in levels of ALT (MD = 2.66 (-1.56, 6.87), <i>p</i> = 0.22), AST (MD = -1.99 (-5.70, 1.72), <i>p</i> = 0.29), GGT (MD = 5.02 (-0.86, 10.90), <i>p</i> = 0.09), ALP (MD = -5.16 (-11.90, 1.59), <i>p</i> = 0.13), TC (MD = -0.31 (-0.65, 0.03), <i>p</i> = 0.07), or TG (MD = -0.14 (-0.53, 0.25), <i>p</i> = 0.48). The HbA<sub>1c</sub> (%) level was found to be significantly reduced in the liraglutide arm (MD = -0.62 (-0.88, -0.36), <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>Liraglutide effectively improves the lipid profile in patients with NASH.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 1","pages":"100-109"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/ea/PG-18-46209.PMC10050979.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2022.112775","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease, but no drug therapies have been approved to date. While glucagon-like peptide-1 (GLP-1) analogues may help in the management, the existing evidence remains conflicting.
Aim: This meta-analysis aims to elucidate the efficacy of liraglutide in patients with NASH.
Material and methods: We searched 4 databases for randomized controlled trials assessing the efficacy of liraglutide in patients with NASH. We analysed continuous outcomes using the mean difference (MD) and relative 95% confidence interval (CI), while dichotomous outcomes were analysed using the risk ratio (RR) and relative 95% CI. Primary endpoints included alanine aminotransferase (ALT) (IU/l), aspartate aminotransferase (AST) (IU/l), alkaline phosphatase (ALP) (IU/l), and γ-glutamyl transferase (GGT) (IU/l). Secondary outcomes were body mass index (BMI) (kg/m2), waist circumference (cm), total cholesterol (TC) (mmol/l), triglyceride (TG) (mmoll), high-density lipoprotein (HDL) (mmol/l), low-density lipoprotein (LDL) (mmol/l), and glycated hemoglobin (HbA1c) (%).
Results: A total of 5 clinical trials were included. The analysis showed that liraglutide is effective in increasing HDL (MD = +0.10 (-0.18, -0.02), p = 0.02) and reducing LDL levels in blood (MD = -0.29 (-0.56, -0.02), p = 0.04). No significant difference was noted in levels of ALT (MD = 2.66 (-1.56, 6.87), p = 0.22), AST (MD = -1.99 (-5.70, 1.72), p = 0.29), GGT (MD = 5.02 (-0.86, 10.90), p = 0.09), ALP (MD = -5.16 (-11.90, 1.59), p = 0.13), TC (MD = -0.31 (-0.65, 0.03), p = 0.07), or TG (MD = -0.14 (-0.53, 0.25), p = 0.48). The HbA1c (%) level was found to be significantly reduced in the liraglutide arm (MD = -0.62 (-0.88, -0.36), p < 0.01).
Conclusions: Liraglutide effectively improves the lipid profile in patients with NASH.
期刊介绍：
Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
